The CD28-B7 costimulatory pathway and its role in autoimmune disease

Journal of Leukocyte Biology

Volumn 62, Issue 2, 1997, Pages 156-162

  Daikh, David ^a   Wofsy, David ^a   Imboden, John B ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antigen presenting cells; Self antigens

Indexed keywords

CD28 ANTIGEN; CD4 ANTIGEN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; AUTOIMMUNITY; DIAGNOSIS; ETIOLOGY; IMMUNE RESPONSE; IMMUNOMODULATION; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE RECEPTOR GENE;

ANIMALIA; MURINAE;

EID: 0030822295     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1002/jlb.62.2.156     Document Type: Review

References (80)

1. Bretscher, P., Cohen, M. (1970) A theory of self-nonself discrimination. Science 169, 1042-1049.
2. Mueller, D. L., Jenkins, M. K., Schwartz, R. H. (1989) Clonal expansion vs. functional clonal activation: a costimulatory pathway determines the outcome of T cell receptor occupancy. Annu. Rev. Immunol. 7, 445-480.
3. Linsley, P. S., Ledbetter, J. A. (1993) The role of the CD28 receptor during T cell responses to antigen. Annu. Rev. Immunol. 11, 191-212.
4. Bluestone, J. A. (1995) New perspectives of CD28-B7-mediated T cell costimulation. Immunity 2, 555-559.
5. Azuma, M., Ito, D., Yagita, H., Okumura, K., Phillips, J. H., Lanier, L. L., Somoza, C. (1993) B70 antigen is a second ligand for CTLA-4 and CD28. Nature 366, 76.
6. Lenschow, D. J., Su, G. H., Zuckerman, L. A., Nabavi, N., Jellis, C. L., Gray, G. S., Miller, J., Bluestone, J. A. (1993) Expression and functional significance of an additional ligand for CTLA-4. Proc. Natl. Acad. Sci. USA 90, 11054.
7. Hathcock, K. S., Laszlo, G., Dickler, H. B., Bradshaw, J., Linsley, P., Hodes, R. J. (1993) Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. Science 262, 905.
8. Freeman, G. J., Borriello, F., Hodes, R. J., Reiser, H., Hathcock, K. S., Laszlo, G., McKnight, A. J., Kim, J., Du, L., Lombard, D. B., Gray, G. S., Nadler, L. M., Sharpe, A. H. (1993) Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science 262, 907.
9. Inaba, K., Witmer-Pack, M., Inaba, M., Hathcock, K. S., Sakuta, H., Azuma, M., Yagita, H., Okumura, K., Linsley, P. S., Ikehara, S., Muramatsu, S., Hodes, R. J., Steinman, R. M. (1994) The tissue distribution of the B7-2 costimulatory molecule in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J. Exp. Med. 180, 1849-1860.
10. Hathcock, K. S., Lazlo, G., Pucillo, C., Linsley, P., Hodes, R. J. (1994) Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J. Exp. Med. 180, 631-640.
11. Linsley, P. S., Brady, W., Urnes, M., Gorsmaire, L., Damle, N. K., Ledbetter, J. A. (1991) CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174, 561.
12. Krummel, M. F., Allison, J. P. (1995) CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182, 459-465.
13. + T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. J. Immunol. 155, 1032-1036.
14. Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Greisser, H., Mak, T. W. (1995) Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270, 985-988.
15. Linsley, P. S., Greene, J. L., Brady, W., Bajorath, J., Ledbetter, J. A., Peach, R. (1994) Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1, 793-801.
16. Van Der Merwe, P. A., Bodian, D. L., Daenke, S., Linsley, P., Davis, S. J. (1997) CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J. Exp. Med. 185, 393-404.
17. Shahinian, A., Pfeffer, K., Lee, K. P., Kundig, T. M., Kishihara, K., Wakeham, A., Kawai, K., Ohasi, P., Thompson, C. B., Mak, T. W. (1993) Differential T cell costimulatory requirements in CD28-deficient mice. Science 261, 609-612.
18. Green, T. M., Noel, P. J., Sperling, A. I., Walunas, T. L., Gray, G. S., Bluestone, J. A., Thompson, C. B. (1994) Absence of B7-dependent responses in CD28-deficient mice. Immunity 1, 501-508.
19. Thompson, C. B., Lindsten, T., Ledbetter, J. A., Kinkel, S. L., Young, H. A., Emerson, S. G., Leiden, J. M., June, C. H. (1989) CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc. Natl. Acad. Sci. USA 86, 1333-1337.
20. Harding, F. A., McArthur, J. G., Gross, J. A., Raulet, D. H., Allison, J. P. (1992) CD28-mediated signaling co-stimulates murine T cells and prevents induction of anergy in T cell clones. Nature 356, 607.
21. Lindstein, T., June, C. H., Ledbetter, J. A., Stella, G., Thompson, C. B. (1989) Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science 244, 339.
22. Fraser, J. D., Irving, B. A., Crabtree, G. R., Weiss, A. (1991) Regulation of Interleukin-2 enhancer activity by the T cell accessory molecule CD28. Science 251, 313-316.
23. Gimmi, C. D., Freeman, G. J., Gribben, J. G., Sugita, K., Freedman, A. S., Morimoto, C., Nadler, L. M. (1991) B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc. Natl. Acad. Sci. USA 88, 6575-6579.
24. Harding, F. A., McArthur, J. G., Gross, J. A., Raulet, D. H., Allison, J. P. (1992) CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356, 607-609.
25. L. Immunity 3, 87-98.
26. Vandengerghe, P., Freeman, G. J., Nadler, L. M., Fletcher, M. C., Kamoun, M., Turka, L. A., Ledbetter, J. A., Thompson, C. B., June, C. H. (1992) Antibody and B7/BB1-mediated ligation of the CD28 receptor induces tyrosine phosphorylation in human T cells. J. Exp. Med. 175, 951-960.
27. ras. J. Exp. Med. 180, 1067-1076.
28. Boucher, L. M., Wiegman, K., Futterer, A., Pfeffer, K., Machleidt, T., Shutze, S., Mak, T. W., Kronke, M. (1995) CD28 signals through acidic sphingomyelinase J. Exp. Med. 181, 1949.
29. Su, B., Jacinto, E., Hibi, M., Kallunki, T., Karin, M., Ben-Neriah, Y. (1994) JNK is involved in signal integration during costimulation of T lymphocytes. Cell 77, 727-736.
30. Ward, S. G., Westwick, J., Hall, N. D., Sansom, D. M. (1993) Ligation of CD28 receptor by B7 induces formation of D-3 phosphomositides in T lymphocytes independently of T cell receptor/CD3 activation. Eur. J. Immunol. 23, 2572-2577.
31. Truitt, K. E., Hicks, C. M., Imboden, J. B. (1994) Stimulation of CD28 triggers an association between CD28 and phosphatidylinositol 3-kinase. J. Exp. Med. 179, 1071-1076.
32. Prasad, K. V. S., Cai, Y.-C., Raab, M., Duckworth, B., Cantley, L., Shoelson, S. E., Rudd, C. E. (1994) T-cell antigen CD28 interacts with the lipid kinase phosphatidylinositol 3-kinase by a cytoplasmic Tyr(P)-Met-Xaa-Met motif. Proc. Natl. Acad. Sci. USA 91, 2834-2838.
33. Stein, P. D., Fraser, J. D., Weiss, A. (1994) The cytoplasmic domain of CD28 is both necesssary and sufficient for costimulation of interleukin-2 secretion and association with phosphatidylinositol 3′-kinase. Mol. Cell. Biol. 14, 3392-3402.
34. Pages, F., Rageneau, M., Rottapel, R., Truneh, A., Nunes, J., Imbert, J., Olive, D. (1994) Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling. Nature 369, 327-329.
35. Prasad, K. V. S., Cai, Y.-C., Raab, M., Duckworth, B., Cantley, L., Shoelson, S. E., Rudd, C. E. (1994) T cell antigen CD28 interacts with the lipid kinase phosphatidylinositol 3-kinase by a cytoplasmic Tyr(P)-Met-Xaa-Met motif. Proc. Natl. Acad. Sci. USA 91, 2834-2838.
36. Truitt, K. E., Hicks, C. M., Imboden, J. B. (1994) Stimulation of CD28 triggers an association between CD28 and phosphatidylinositol 3-kinase in Jurkat T cells. J. Exp. Med. 179, 1071-1076.
37. 1-integrin adhesion involves phosphatidylinositol 3-kinase. J. Immunol. 156, 883-886.
38. Chen, C., Nabavi, N. (1994) In vitro induction of T cell anergy by blocking B7 and early T cell costimulatory molecule ETC-1/B7-2. Immunity 1, 147-154.
39. deBoer M., Kasran, A., Kwekkeboom, J., Walter, H., Vandenberghe, P., Ceuppens, J. L. (1993) Ligation of B7 with CD28/CTLA-4 on T cells results in CD40 ligand expression, interleukin-4 secretion and efficient help for antibody production by B cells. Eur. J. Immunol. 23, 3120.
40. Linsley, P. S., Wallace, P. M., Johnson, J., Gibson, M. G., Greene, J. L., Ledbetter, J. A., Singh, C., Tepper, M. A. (1992) Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 257, 792.
41. Turka, L. A., Linsley, P. S., Lin, H., Brady, W., Leiden, J. M., Wei, R. Q., Gibson, M. L., Zheng, X. G., Myrdal, S., Gordon, D. (1992) T cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc. Natl. Acad. Sci. USA 89, 11102.
42. Lenschow, D. J., Zeng, Y., Thistlethwaite, J. R., Montag, A., Brady, W., Gibson, M. G., Linsley, P. S., Bluestone, J. A. (1992) Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 257, 789.
43. Finck, B., Linsley, P., Wofsy, D. (1994) Treatment of murine lupus with CTLA4Ig. Science 265, 1225.
44. Steinberg, A. D., Raveche, E. S., Laskin, C. A., Smith, H. R., Santoro, T., Miller, M. L., Plotz, P. H. (1984) Systemic lupus erythematosus: insights from animal models. Ann. Intern. Med. 100, 714.
45. 1 mice with monoclonal antibody L3T4. J. Exp. Med. 161, 378.
46. Wofsy, D., Seaman, W. E. (1987) Reversal of advanced murine lupus in NZB/NZW mice by treatment with monoclonal antibody to L3T4. L. Immunol. 138, 3247.
47. Pozzilli, P., Signore, A., Williams, A. J., Beales, P. E. (1993) NOD mouse colonies around the world: recent facts and figures. Immunol. Today 14, 193-196.
48. Koike, T., Itoh, Y., Ishi, T., Ito, I., Takabayashi, K., Maruyama, N., Tomioka, H., Yoshida, S. (1987) Preventive effect of monoclonal anti-L3T4 antibody on development of diabetes in NOD mice. Diabetes 36, 539-541.
49. Lenschow, D. J., Ho, S. C., Sattar, H., Rhee, L., Gray, G., Nabavi, N., Herold, K. C., Bluestone, J. A. (1995) Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med. 181, 1145-1155.
50. Arnason, B. G. (1983) Relevance of experimental autoimmune encephalomyelitis to multiple sclerosis. Neurol. Clin. 1, 765.
51. Touhy, V. K., Lo, Z., Sobel, R. A., Laursen, R. A., Lees, M. B. (1989) Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice. J. Immunol. 142, 1523-1527.
52. + T cells is required for entry into brain parenchyma. J. Exp. Med. 177, 57-68.
53. Ando, D. G., Clayton, J., Kono, D., Urban, J. L., Sercarz, E. E. (1989) Encephalitogenic cells in the B10.PL model of experimental autoimmune encephalomyelitis (EAE) are of the Th1 lymphokine susbet. Cell. Immunol. 124, 132-143.
54. McRae, B. L., Kennedy, M. K., Tan, L. J., Dal Canto, M. A., Miller, S. D. (1992) Induction of active and adoptive chronic-relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein. J. Neuroimmunol. 38, 229-240.
55. Cross, A. H., Girard, T. S., Giacolelto, K. S., Evans, R. S., Keeling, R. M., Lin, R. F., Trotter, J. L., Karr, R. W. (1995) Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA4-Fc supports a key role for CD28 costimulation. J. Clin. Invest. 95, 2783-2789.
56. Hancock, W. H. (1995) CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J. Immunol. 155, 4521-4524.
57. Perrin, P. J., Scott, D., Quigley, L., Albert, P. S., Feder, O., Gray, G. S., Abe, R., June, C. H., Racke, M. K. (1995) Role of B7:CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis. J. Immunol. 154, 1481-1490.
58. Miller, S. D., Vanderlugt, C. L., Lenschow, D. J., Pope, J. G., Karandikar, N. J., Dal Canto, M. C., Bluestone, J. A. (1995) Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. Immunity 3, 739-745.
59. Khoury, S. J., Gallon, L., Venburg, R. R., Chandraker, A., Peach, R., Linsley, P. S., Turka, L. A., Hancock, W. H., Sayegh, M. H. (1996) Ex vivo treatment of antigen-presenting cells with CTLA4Ig and encephalitogenic peptide prevents experimental autoimmune encephalomyelitis in the Lewis rat. J. Immunol. 157, 3700-3705.
60. Knoerzer, D. B., Karr, R. W., Schwartz, B. D., Mengle-Gaw, L. J. (1995) Collagen-induced arthritis in the BB rat. J. Clin. Invest. 96, 987-993.
61. Griggs, N. D., Agersborg, S. S., Noelle, R. J., Ledbetter, J. A., Linsley, P. S., Tung, K. S. K. (1996) The relative contribution of the CD28 and gp39 costimulatory pathways in the clonal expansion of pathogenic acquisition of self-reactive T cells. J. Exp. Med. 183, 801-810.
62. Nishikawa, K., Linsley, P. S., Collins, A. B., Stamenkovic, I., McCluskey, R. T., Andres, G. (1994) Effect of CTLA4 chimeric protein on rat autoimmune anti-glomerular basement membrane glomerulonephritis. Eur. J. Immunol. 24, 1249-1254.
63. Milich, D. R., Linsley, P. S., Hughes, J. L., Jones, J. E. (1994) Soluble CTLA-4 can suppress autoantibody production and elicit long term unresponsiveness in a novel transgenic model. J. Immunol. 153, 429.
64. Genain, C. P., Abel, K., Belmar, N., Villinger, F., Rosenberg, D. P., Lenington, C., Raine, C. S., Hauser, S. L. (1996) Late complications on immune deviation therapy in a nonhuman primate. Science 274, 2054-2057.
65. Kuchroo, V. K., Das, M. P., Brown, J. A., Ranger, A. M., Zamvil, S. S., Sobel, R. A., Weiner, H. L., Nabavi, N., Glimcher, L. H. (1995) B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80, 707-718.
66. Freeman, G. J., Boussiotis, V. A., Anumanthan, A., Bernstein, G. M., Ke, X-Y., Rennert, P. D., Gray, G. S., Gribben, J. G., Nadler, L. M. (1995) B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 2, 523-532.
67. Tian, J., Clare-Salzler, M., Herschenfeld, A., Middleton, B., Newman, D., Mueller, R., Arita, S., Evans, C., Atkinson, M. A., Mullen, Y., Sarvetnick, N., Tobin, A. J., Lehmann, P. V., Kaufman, D. L. (1996) Modulating autoimmune responses to GAD inhibitis disease progression and prolongs islet graft survival in diabetes-prone mice. Nature Med. 2, 1348-1353.
68. Lenschow, D., Herold, K. C. Rhee, L., Patel, B., Koons, A., Qin, H-Y., Fuchs, E., Singh, B., Thompson, C. B. Bluestone, J. A. (1996) CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 5, 285-293.
69. Herold, K. C., Vezys, V., Koons, A., Lenschow, D., Thompson, C., Bluestone, J. A. (1997) CD28/B7 costimulation regulates autoimmune diabetes induced with multiple low doses of streptozotocin. J. Immunol. 158, 984-991.
70. Nakajima, A., Azuma, M., Kodera, S., Nuriya, S., Terashi, A., Abe, M., Hirose, S., Shirai, T., Yagita, H., Okumura, K. (1995) Preferential dependence of autoantibody production in murine lupus on CD86 co-stimulatory molecule. Eur. J. Immunol. 25, 3060-3069.
71. Perrin, P. J., Maldanado, J. H., Davis, T. A., June, C. H., Racke, M. K. (1996) CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J. Immunol. 157, 1333-1336.
72. Karandikar, N. J., Vanderlugt, C. L., Walunas, T. L., Miller, S. D., Bluestone, J. A. (1996) CTLA-4: a negative regulator of autoimmune disease. J. Exp. Med. 184, 783-788.
73. Durie, F. H., Foy, T. M., Masters, S. R., Laman, J. D., Noelle, R. J. (1994) The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol. Today 15, 406-410.
74. Allen, R. C., Armitage, R. J., Conley, M. E., Rosenblatt, H., Jenkins, N. A., Copeland, N. G., Bedell, M. A., Edelhoff, S., Disteche, C. M., Simoneaux, D. K., Fanslow, W. C, Belmont, J., Spriggs, M. K. (1993) CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 259, 990.
75. Aruffo, A., Farrington, M., Hollenbaugh, D., Li, X., Milatovich, A., Nonoyama, S., Bajorath, J., Grosmaire, L. S., Stenkamp, R., Neubauer, M., Roberts, R. L., Noelle, R. J., Ledbetter, J. A., Francke, U., Ochs, H. D. (1993) The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 72, 291-300.
76. Grewal, I. S., Foellmer, H. G. Grewal, K. D., Xu. J., Hardardottir, F., Baron, J. L., Janeway, C. A., Flavell, R. A. (1996) Requirement for CD40 ligand in costimulation induction. T cell activation, and experimental autoimmune encephalomyelitis. Science 273, 1864-1867.
77. Durie, F. H., Fava, R. A., Foy, T. M., Aruffo, A., Ledbetter, J. A., Noelle, R. J. (1993) Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 261, 1328-1330.
78. Early, G. S., Weiguo, Z., Burns, C. M. (1996) Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand Black x New Zealand White mice. J. Immunol. 157, 3159-3164.
79. Mohan, C., Shi, Y., Laman, J. D., Datta, S. K. (1995) Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J. Immunol. 154, 1470-1480.
80. Daikh, D., Wofsy, D. (1997) Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/CD40L costimulation pathways. J. Immunol., in press.